I'm LongbridgeAI, I can summarize articles.Bell Potter analyst John Hester has maintained a Buy rating on Imugene (IUGNF) with a price target of A$0.25. The analyst consensus on Imugene is a Moderate Buy, also with an average price target of A$0.25. Hester has an average return of 11.5% and a 51.08% success rate on his stock recommendations.
Bell Potter analyst John Hester maintained a Buy rating on Imugene today and set a price target of A$0.25.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Clarity Pharmaceuticals Ltd., and Imugene. According to TipRanks, Hester has an average return of 11.5% and a 51.08% success rate on recommended stocks.
Currently, the analyst consensus on Imugene is a Moderate Buy with an average price target of A$0.25.